HIT vs HIMS

For growth investors, Health In Tech, Inc.

(HIT) is the stronger pick with 71. 0% revenue growth year-over-year, versus 59. 0% for Hims & Hers Health, Inc. (HIMS). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 50. 3x trailing P/E (51. 5x forward), making it the more compelling value choice. Analysts rate Hims & Hers Health, Inc. (HIMS) a "Hold" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Hims & Hers Health, Inc.

(HIMS) is the cheapest at 50. 3x versus Health In Tech, Inc. at 78. 5x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -69. 2% for Health In Tech, Inc. (HIT). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus HIT's -69. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Health In Tech, Inc.

(HIT) is the lower-risk stock at 2. 00β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 20% more volatile than HIT relative to the S&P 500. On balance sheet safety, Health In Tech, Inc. (HIT) carries a lower debt/equity ratio of 1% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Health In Tech, Inc.

(HIT) is pulling ahead at 71. 0% versus 59. 0% for Hims & Hers Health, Inc. (HIMS). On earnings-per-share growth, the picture is similar: Health In Tech, Inc. grew EPS 62. 6% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIT leads at 79. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus 3. 8% for Health In Tech, Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus 4. 6% for HIT. At the gross margin level — before operating expenses — HIT leads at 62. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hims & Hers Health, Inc.

(HIMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+161. 9% 10Y return). Health In Tech, Inc. (HIT) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HIMS: +161. 9%, HIT: -69. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HIT (Technology) and HIMS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.